Join our community of smart investors

Genus prepares for disease threat

These numbers may have been hurt by an outbreak of African swine fever in China, but there are still opportunities on the horizon
September 6, 2018

Investors reading the statutory numbers from animal genetics specialist Genus (GNS) have every right to be worried – slowing revenue growth and a sharp decline in pre-tax profits hardly sounds like good news. But ignore negative currency movements and one-off charges associated with the revaluation of Genus’s bovine assets, and the 6 per cent share price fall on results day seems unjustified. On an underlying basis, revenue and pre-tax profits actually rose 6 per cent and 9 per cent, respectively.

IC TIP: Hold at 2590p
This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in